As used herein, the term ???a disorder in which A??(20-42) globulomer activity and/or any other A??-form that comprises the globulomer epitope with which the antibodies of the present invention are reactive is detrimental??? is intended to include diseases and other disorders in which the presence of A??(20-42) globulomer and/or any other A?? form that comprises the globulomer epitope with which t